http://highlightllpharma.com/en.php/news/show/id/1348 WebJul 3, 2024 · July 3, 2024 2:04 AM UTC. Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against the same targets to treat a broad range of autoimmune diseases. Both compounds would need to find a foothold in a ...
TLL018 / Highlightll Pharma
WebMar 28, 2024 · Highlightll got $10 million in cash upfront in the deal in addition to $10 million in Biohaven equity, development and commercial milestone payments of up to $950 million and tiered royalty payments. WebMar 22, 2024 · Highlightll will receive $10 million in upfront cash and $10 million in Biohaven equity, development and commercial milestone payments of up to $950 million, and … the golden anniversary of the thymus
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, …
WebHIGHLIGHTLL PHARMA High Impact Medicines for All We strive to discover breakthrough medicines which would have high impact on health care. We are not limited to one region … Highlightll Pharmaceutical (USA) LLC Add：485C US Highway 1 South, Ste. … Highlightll Pharmaceutical TLL-018 Achieved Breakthrough Results in a … Our policy on responding to requests to provide access to our investigational … We strive to discover breakthrough medicines which would have high impact … WebHighlightll Pharmaceutical (usa) LLC * 1 Principals See who the company's key decision makers are 9 See similar companies for insight and prospecting. Start Your Free Trial … WebMar 22, 2024 · Highlightll was founded by Chris Liang PhD and is focused on the research and development of small molecules for the treatment of autoimmune and inflammatory disorders. Dr. Liang is a Princeton... theater huub stapel